Results grade1 grade2 grade3 (1) Can we identify metabolites or metabolic pathways that are associated with breast cancer clinical parameters? Alex-CIS-GCTOF.

Slides:

Advertisements

Similar presentations

TOP2A IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN UNSELECTED BREAST CANCER Amit Pancholi Molecular Profiling of Breast Cancer: Predictive Markers of Long.

Advertisements

Ismail Jatoi, MD, PhD, FACS Dale H. Dorn Chair in Surgery Professor and Chief, Division of Surgical Oncology University of Texas Health Science Center.

Triple-Negative Breast Cancer

Tumor CompartmentStromal Compartment mask C D EF A B Supplemental Fig 1. Epithelial and stromal PD-L1 expression. AQUA scores for PD-L1 in the epithelium.

Gene regulation in cancer 11/14/07. Overview The hallmark of cancer is uncontrolled cell proliferation. Oncogenes code for proteins that help to regulate.

Metabonomics A New Potential Diagnostic Tool David Huffman Western Michigan University WDA 2010.

Gene Co-expression Network Analysis BMI 730 Kun Huang Department of Biomedical Informatics Ohio State University.

Additional Pathways in Carbohydrate Metabolism

Cell Signaling Lecture 10. Receptor Tyrosine Kinases Regulate cell proliferation, differentiation, cell survival and cellular metabolism The signaling.

Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.

MammaPrint, the story of the 70-gene profile

NUCLEOTIDES AND NUCLEIC ACIDS

Perspectives of metabolomics towards personalized medicine

Table S1. Characteristics of breast tumor and normal breast tissue samples. Relevant characteristics of breast tumor and normal breast tissue samples analyzed.

Supplemental Figures Loss of circadian clock gene expression is associated with tumor progression in breast cancer Cristina Cadenas 1*, Leonie van de Sandt.

FUNCTIONAL GENOMICS REVEAL THAT THE SERINE SYNTHESIS PATHWAY IS ESSENTIAL IN BREAST CANCER Introduction: Tim Butler Spellman Lab.

TCA & Pentose Phosphate Pathway 12/01/2009. Citrate Synthase.

Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.

Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.

Breast Cancer Risk with Menopausal Hormone Use Jackie Bouillon Advisor: Dr. Robert Hadley Spring 2007.

Other metabolic pathways Pentose phosphate pathway (phosphogluconate pathway) Produces NADPH and ribose 5-phosphate Glc 6-phosphate + 2NADP + + H 2 O 

Station 1 Nucleic Acid – DNA double helix. Station 2 Carbohydrate – Monosaccharide (pentose – ribose)

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,

Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets.

Prognostic and Predictive Factors: Current Evidence for Individualized Therapy Predictive Molecular Markers: Hormone Receptor Status Presented by Kathleen.

Methodology U937 Human Immune Cells Control (No treatment) (n=4) Estrogen (5 uM) (n=4) 4-nonylphenol (5 uM) (n=4) Cultured Cells, RNA Isolation, RT (to.

What are some other organic molecules? Lipids Fats.

WE Presentation #3, Lee et al Cell, “A Lactate-Induced Response to Hypoxia” 2015.

Tumor Marker Phenotype Concordance in Second Primary Breast Cancer Monica Brown, MPH, PhD California Cancer Registry Mary Paré, RN, BS Sutter Cancer Center,

Triple negative (TN) vs. positive (TP) breast cancer (BC) analysis with public genomic data yields AGR3 as a biomarker Anita Umesh, Jenny Park, James Shima,

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.

Clinical Center of the University of Sarajevo

Number of brain metastasis

Figure 1. Correlation between estrogen receptor (ER), progesterone receptor (PR), and Ki-67 expression in primary breast tumors and synchronous axillary.

TRIPLE NEGATIVE BREAST CANCER (TNBC) & ETHNIC MINORITIES

Fig. 2. Kaplan-Meier curves for survival in each breast cancer molecular subtype. Radiologic assessment in triple-negative breast cancer (A), HER2-positive.

Comparison between Pathologic Characteristics of Her2 Negative and Positive Breast Cancer in a Single Cancer Center in Jordan DR Majdi A. Al Soudi, MD,

Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus.

BREAST CANCER A full classification includes histopathological type, grade, stage (TNM), receptor status, and the presence or absence of genes as determined.

2.3-5 Chemical Reactions, Inorganic & Organic Compounds

Nucleic Acids DNA and RNA.

徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2

Breast cancer. Breast cancer. A, antitumor activity of abemaciclib in a human xenograft model (T47D) of ER-positive, HER2-negative breast cancer. Athymic.

Untargeted metabolomics profiling by GC-TOF-MS reveals a human PCa-associated metabolic phenotype in Zn-deficient middle-aged Wistar-Unilever rat prostates.

Figure 1 Metabolic adaptations of cancer cells

Gene expression changes in damaged osteoarthritic cartilage identify a signature of non-chondrogenic and mechanical responses S.L. Dunn, J. Soul, S.

Biochemical pathways proximal to the IDH1 and IDH2 reactions.

Condensed metabolic map of M

Tumor intrinsic subtype is reflected in cancer-adjacent tissue.

Disease-specific survival

Genes affected concordantly within the ileum and meta-analysis data sets formed biofunctional clusters of overlapping pathways. Genes affected concordantly.

Validation of bioinformatic screening of a patient cohort.

Percentages of reactions showing different fluxes at doubled HCO3 levels per group as identified by the solution space sampling of the genome-scale metabolic.

The antitumor activity of olaparib in PDXs identifies a subset of PARPi‐sensitive tumors The antitumor activity of olaparib in PDXs identifies a subset.

20-Year Risks of Breast-Cancer Recurrence

NOAH: pCR Results Patients (%) P=0.002 P=0.003 P=0.29 P=0.43 With T

Volume 2, Issue 3, Pages (March 2016)

General principles of the metabolic processes regulation in the human organism. 1.

Oncogenic indel hotspots.

Tricarboxylic acid (TCA) cycle.

Darshi et al. Am J Nephrol 2016;44: (DOI: / )

Transcripts enriched and depleted in NB TICs compared with SKPs and other tumor tissues. Transcripts enriched and depleted in NB TICs compared with SKPs.

Clustering analysis of DTC-associated genes.

One-way hierarchical cluster analysis of SAM-identified genes using the TMEV software to see the data substructure. One-way hierarchical cluster analysis.

Volume 28, Issue 3, Pages e7 (July 2019)

Detection of microcalcifications in 4T1 mammary tumors and human breast tumor tissue. Detection of microcalcifications in 4T1 mammary tumors and human.

CD36 expression is coordinately regulated in multiple cellular compartments. CD36 expression is coordinately regulated in multiple cellular compartments.

Presentation transcript:

Results grade1 grade2 grade3 (1) Can we identify metabolites or metabolic pathways that are associated with breast cancer clinical parameters? Alex-CIS-GCTOF MS w/ BinBase: 470 detected compounds 161 known metabolites, 309 without identified structure. Partial Least Square (multivariate stats) grade3 grade2 grade1 breast adipose

Results Grade n  1  2  3 tumors show differential up-regulation in Pentose Phosphate Pathway, nucleotides, amino acids, arachidonic acid (but not free fatty acids, gln) production of NADPH, ribose unitsproduction of DNA, RNA

Results Grade n  1  2  3 tumors show differential up-regulation in Pentose Phosphate Pathway, nucleotides, amino acids, arachidonic acid (but not free fatty acids, gln) Amino acids lactate glu  -ala malate citrate n grade C20:4 2HOglutarate n grade IDH1?

Results Can we validate biomarkers in a fully independent study? Cohort 2 (113 patients)

Results Can we validate lipidomic biomarkers in a fully independent study? Cohort 2 (113 patients) Matej Orešič et al. (subm.)

Results Can we validate lipidomic biomarkers in a fully independent study? Immunohistochemistry on tissue slides. Orešič et al. (subm)

Can we get biochemical maps of differential regulation for hormone receptor status? Methods (1)Up to 20% of the identified metabolites lack enzyme annotations. (2)Metabolic endpoint metabolites accumulate more than intermediates. ‘Comprehensive maps’ do not work.

Can we get biochemical maps of differential regulation for hormone receptor status? Methods (1)Up to 20% of the identified metabolites lack enzyme annotations. (2)Metabolic endpoint metabolites accumulate more than intermediates. ‘Comprehensive maps’ do not work.

Chemical and biochemical mapping of metabolomic results Methods

Results Grade 1 tumors vs normal Red nodes: up-regulated in tumors at p<0.05, size ~ x-fold Blue nodes: down-regulated in tumors at p<0.05, size~x-fold Red edges: enzyme substrate/product in KEGGRpair DB Green edges: chemical similarity > 0.7

Methods % of patients Estrogen negativeEstrogen positive triple neg. ER+ PR+ HER2- ER- PR- HER2- single neg. Hormone grade 3

Results Metabolic phenotype of triple negative tumors Patients without Estrogen, Herceptin neu2, Progesteron receptor

Methods % of patients Estrogen negativeEstrogen positive triple neg. ER- PR- HER2+ ER- PR- HER2- double neg. Hormone grade 3

Results Effect of HER2 status on metabolic phenotype of triple negative tumors

Methods % of patients Estrogen negativeEstrogen positive ER+ PR+ HER2- double pos. ER+ PR+ HER2+ triple pos. Hormone grade 2